Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA)

VRCA

Philadelphia, Pennsylvania--(Newsfile Corp. - September 20, 2024) - Current Verrica Pharmaceuticals, Inc (NASDAQ: VRCA) shareholders who have held Verrica shares since prior to May 19, 2021, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Click here to learn more:https://grabarlaw.com/the-latest/verrica-shareholder-investigation/.

Grabar Law Office is investigating claims on behalf of Verrica shareholders. The investigation concerns whether certain officers of Verrica have breached their fiduciary duties owed to the company.

Why:Certain claims as alleged in a recently filed securities fraud class action complaint have survived a motion to dismiss. The underlying securities fraud complaint alleges that Verrica Pharmaceuticals, Inc., via certain of its officers and directors, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On January 11, 2024, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss. Plaintiff was given leave to amend the Complaint, and on September 3, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

Current Verrica shareholders who have held Verrica stock since prior to May 19, 2021, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/verrica-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223981

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today